›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:BRCAvantage™ Plus
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Quest DiagnosticsType:
Laboratory Developed Test
Related tests:
The BRCAvantage™ Plus is a next generation sequencing panel that interrogates all coding regions and up to 50 bases in each intronic region to detect small mutations in the BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, and PALB2 genes. Its Analytical sensitivity: >99% of relevant mutations occurring in the described regions.
Cancer:
Breast Cancer, Ovarian Cancer
Gene:
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDH1 (Cadherin 1), PALB2 (Partner and localizer of BRCA2), PTEN (Phosphatase and tensin homolog), STK11 (Serine/threonine kinase 11)
See More ...
BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), CDH1 (Cadherin 1), PALB2 (Partner and localizer of BRCA2), PTEN (Phosphatase and tensin homolog), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
